<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6853232</article-id><article-id pub-id-type="pmid">31707866</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1680658</article-id><article-id pub-id-type="publisher-id">1680658</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Discovery and evaluation of novel synthetic
5-alkyl-4-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-1-carbox-amide derivatives as
anti-inflammatory agents</article-title><alt-title alt-title-type="running-authors">Q-K Shen et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Qing-Kun</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Guo-Hua</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Gao-</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Mei-</given-names></name><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Li-Hua</given-names></name><xref ref-type="aff" rid="AF0005">
<sup>e</sup>
</xref><xref ref-type="corresp" rid="AN0001"/><xref ref-type="author-notes" rid="FN0002"/></contrib><contrib contrib-type="author"><name><surname>Quan</surname><given-names>Zhe-Shan</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="corresp" rid="AN0002"/><xref ref-type="author-notes" rid="FN0002"/></contrib><aff id="AF0001"><label>a</label><institution>Key Laboratory of Natural Resources and
Functional Molecules of the Changbai Mountain, Affiliated Ministry of Education, College
of Pharmacy, Yanbian University</institution>, Yanji, <country>China</country>; </aff><aff id="AF0002"><label>b</label><institution>Inner Mongolia Autonomous Region Key
Laboratory of Mongolian Medicine Pharmacology for Cardio-Cerebral Vascular
System</institution>, Tongliao, <country>China</country>; </aff><aff id="AF0003"><label>c</label><institution>Affiliated Hospital of Inner Mongolia
University for Nationalities</institution>, Tongliao, <country>China</country>; </aff><aff id="AF0004"><label>d</label><institution>Department of Central Laboratory, Yanbian
University Hospital</institution>, Yanji, <country>China</country>; </aff><aff id="AF0005"><label>e</label><institution>College of Medical, Yanbian
University</institution>, Yanji, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed <underline><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1680658">here</ext-link></underline>.</p></fn><fn id="FN0001"><p>*Qing-Kun Shen and Guo-Hua Gong contributed equally to this work.</p></fn><fn id="FN0002"><p><sup>&#x02021;</sup>Li-Hua Cao and Zhe-Shan Quan are equal correspondence authors. </p></fn><corresp id="AN0001"><bold>CONTACT</bold> L.H. Cao <email>lhcao@ybu.edu.cn</email><institution>College of Medical, Yanbian University</institution>, Yanji, Jilin 133002,
<country>China</country>; </corresp><corresp id="AN0002">Z. S. Quan <email>zsquan@ybu.edu.cn</email><institution>Key Laboratory of Natural Resources and Functional Molecules of the Changbai
Mountain, Affiliated Ministry of Education, College of Pharmacy, Yanbian
University</institution>, Yanji, Jilin 133002, <country>China</country></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2019</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="9">85</fpage><lpage>95</lpage><history><date date-type="received"><day>22</day><month>4</month><year>2019</year></date><date date-type="rev-recd"><day>23</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>09</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as
Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1680658.pdf"/><abstract><title>Abstract</title><p>To develop novel anti-inflammatory agents, a series of 5-alkyl-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide derivatives were designed, synthesised, and
evaluated for anti-inflammatory effects using RAW264.7 cells. Structures of the
synthesised compounds were determined using <sup>1</sup>H NMR, <sup>13&#x02009;</sup>C NMR, and
HRMS. All the compounds were screened for anti-inflammatory activity based on their
inhibitory effects against LPS-induced NO release. Among them,
5-(3,4,5-trimethoxybenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (<bold>6p</bold>) showed the highest
anti-inflammatory activity and inhibited NO release more potently than the lead compound
<bold>D1</bold>. Further studies revealed that compound <bold>6p</bold> reduced the
levels of NO, TNF-&#x003b1;, and IL-6, and that its anti-inflammatory activity involves the
inhibition of COX-2 and iNOS and downregulation of the mitogen-activated protein kinases
(MAPK) signal pathway. Notably, compound <bold>6p</bold> displayed more prominent
anti-inflammatory activity than <bold>D1</bold> and the positive control ibuprofen in the
<italic>in vivo</italic> acute inflammatory model. Overall, these findings indicate that
compound <bold>6p</bold> is a therapeutic candidate for the treatment of inflammation.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Synthesis</kwd><kwd>anti-inflammatory activity</kwd><kwd>NO</kwd><kwd>MAPKs</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">National Natural Science Foundation of
China</named-content><named-content content-type="funderidentifier">10.13039/501100001809</named-content></funding-source><award-id>21662036</award-id><award-id>81660837</award-id><award-id>81760627</award-id><award-id>81660579</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Science and Technology Planning Projects from
the Education Commission of Jilin Province of China</named-content></funding-source><award-id>JJKH20191136KJ</award-id></award-group><funding-statement>This work was supported by the National Natural Science Foundation of
China (No. 21662036, 81660837, 81760627, 81660579) and Science and Technology Planning
Projects from the Education Commission of Jilin Province of China
(JJKH20191136KJ).</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="11"/><word-count count="7405"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>Inflammation is a protective host immune response to noxious stimuli, injury, or
infection<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Long-term chronic
inflammation, however, can cause increased vascular permeability, fibrosis, and tissue
damage and can lead to the development of metabolic disorders such as rheumatoid arthritis,
atherosclerosis, and even cancer<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>.
It is well known that the use of chemical drugs to inhibit inflammation is an effective way
to alleviate the symptoms of inflammation-related diseases<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. Nonsteroidal anti-inflammatory drugs (NSAIDs) are still widely
used in clinical applications today. However, they usually cause unexpected side effects,
such as peptic ulcers, bleeding, mucosal lesions, and nephrotoxicity<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. It is, therefore, better to find novel anti-inflammatory compounds
with fewer adverse reactions.</p><p>As a congenital immune cell, macrophages play an important role in the occurrence and
development of inflammation. During inflammation, macrophages overexpress bioactive
inflammatory mediators such as nitric oxide (NO), interleukin 6 (IL-6), and tumour necrosis
factor-alpha (TNF-&#x003b1;)<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. Furthermore,
the accumulation of these inflammatory mediators can cause cell and tissue damage and
eventually chronic inflammation<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>. The
inhibition of cytokine release from activated macrophages is, therefore, an important mode
of action of anti-inflammatory drugs. The mitogen-activated protein kinases (MAPKs) are a
family of signal transduction proteins that include extracellular signal-regulated kinase
(ERK), c-Jun N-terminal kinases (JNK), and the p38 isoform (p38), which are involved in the
classical pathways that modulate immune-mediated inflammatory responses through the
corresponding signalling cascades<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>.
Activated MAPKs modify the phosphorylation of the threonine/tyrosine motifs, accelerating
iNOS, COX-2, and pro-inflammatory cytokine expression (including NO, TNF-&#x003b1;, and IL-6) in the
activated macrophages<xref rid="CIT0012" ref-type="bibr"><sup>12&#x02013;14</sup></xref>. Thus, the pharmacological interference or inhibition of the MAPK
signalling pathway can effectively alleviate the occurrence and development of inflammation.
Development of anti-inflammatory agents that target the MAPK pathway might be an attractive
therapeutic approach.</p><p>In previous studies, we presented many different derivative series with significant
anti-inflammatory activities in an <italic>in vivo</italic> xylene-induced ear-oedema
model<xref rid="CIT0015" ref-type="bibr"><sup>15&#x02013;18</sup></xref>.
A series of 6-substituted-[1, 2, 4]triazolo[3,4-a]phthalazine-3-carboxamide derivatives
(<bold>D</bold>) were found to be especially effective anti-inflammatory agents <italic>in
vitro</italic> and <italic>in vivo</italic><xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>. Among them, compounds <bold>A1</bold><xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>, <bold>B1</bold><xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, <bold>C1</bold><xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>, and <bold>D1</bold><xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref> were shown to be the most active derivatives in each series, and
their structures are shown in <xref ref-type="fig" rid="F0001">Figure 1</xref>. Structure
analysis of these derivatives revealed the following: (a) a tricyclic skeleton that contains
a triazole ring; and (b) a triazole, 3-amino triazole, or 3-amido triazole that was assumed
to be the main pharmacological moiety conferring the anti-inflammatory effect. In addition,
functional group transitions and flipping are classic and effective strategies for the
rational optimisation of lead compounds<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Design of target compounds <bold>6a&#x02013;6t</bold>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1680658_F0001_C"/></fig><p>As part of our continuous efforts to develop better novel anti-inflammatory agents and
based on the above observations, a series of 5-alkyl-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide derivatives (<bold>6a&#x02013;6t</bold>) were designed
and synthesised using the lead compound <bold>D</bold> and the design principles of skeleton
migration and functional group flipping. Moreover, the anti-inflammatory effects of these
target compounds were evaluated in RAW264.7 cells following lipopolysaccharide (LPS)-induced
NO production. Further, the most potent compound, <bold>6p</bold>, with a
3,4,5-trimethoxybenzyl moiety, was subjected to preliminary studies to determine the
mechanisms of action underlying its anti-inflammatory activity by western blotting. Finally,
we confirmed the anti-inflammatory effects <italic>in vivo</italic> by using the carrageenan
method.</p></sec><sec id="s0002"><label>2.</label><title>Materials and methods</title><sec id="s0003"><label>2.1.</label><title>Chemistry</title><p>All chemicals were purchased from commercial source and used without further purification
unless otherwise stated. The reactions were monitored by TLC using Merck Kieselgel 60&#x02009;F
254 plates and visualised under UV light at 254&#x02009;nm. Column chromatography was generally
performed on silica gel (200 mesh size).<sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra
were measured on an AV-300 (Bruker BioSpin, Switzerland) and all chemical shifts were
given in ppm relative to tetramethylsilane (TMS). High-resolution mass spectra (HRMS) were
measured with an Thermo Scientific LTQ Orbitrap XL in ESI mode (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1680658">Supplementary material</ext-link>).</p></sec><sec id="s0004"><label>2.2.</label><title>Procedure for the synthesis of compound 2</title><p>A mixture of benzene-1,2-diamine (<bold>1</bold>) (10.0&#x02009;g, 92&#x02009;mmol), oxalic acid
(12.50&#x02009;g, 139&#x02009;mmol), and 30.00&#x02009;ml 10% HCl in 30&#x02009;ml H<sub>2</sub>O was stirred at 100&#x02009;&#x000b0;C
for 2&#x02009;h. The mixture was cooled and then filtered to obtain
1,4-dihydroquinoxaline-2,3-dione (<bold>2</bold>) as a white solid. Yield: 93%, m.p.
&#x0003e;300&#x02009;&#x000b0;C. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>: 7.06&#x02013;7.15
(m, 4H, Ar-H), 11.92 (s, 2H, &#x02013;CONH&#x02013;).</p></sec><sec id="s0005"><label>2.3.</label><title>Procedure for the synthesis of compound 3</title><p>A solution of compound 2 (5.0&#x02009;g, 46&#x02009;mmol) in hydrazine hydrate (100&#x02009;ml) was stirred at
100&#x02009;&#x000b0;C for 2&#x02009;h. The mixture was cooled and then filtered to obtain
3-hydrazinylquinoxalin-2(1<italic>H</italic>)-one (<bold>3</bold>) as a yellow solid.
Yield: 84%, m.p. &#x0003e;300&#x02009;&#x000b0;C. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz)
<italic>&#x003b4;</italic>: 4.52 (s, 2H, NH<sub>2</sub>), 7.11&#x02013;7.37 (m, 4H, Ar-H), 8.37 (s, 1H,
&#x02013;NH&#x02013;), 12.07 (s, 1H, &#x02013;CONH&#x02013;).</p></sec><sec id="s0006"><label>2.4.</label><title>Procedure for the synthesis of compound 4</title><p>To a suspension of compound <bold>3</bold> (1.3&#x02009;g, 5&#x02009;mmol) in diethyl oxalate (15&#x02009;ml) was
stirred at reflux for 3&#x02009;h. The solvent was removed under reduced pressure to give light
yellow oil. The crude residue was purified by silica gel column chromatography (EtOAc) and
recrystallized from petroleum ether to give compound <bold>4</bold>, yield: 34%.</p></sec><sec id="s0007"><label>2.5.</label><title>General procedure for the synthesis of compound (5a&#x02013;5t)</title><p>A mixture of compound <bold>4</bold> (0.52&#x02009;g, 2&#x02009;mmol), K<sub>2</sub>CO<sub>3</sub>
(0.28&#x02009;g, 2&#x02009;mmol) and all kinds of halogenated alkanes (2.4&#x02009;mmol) in DMF (25&#x02009;ml) was
stirred at 50&#x02009;&#x000b0;C for 3&#x02013;5&#x02009;h monitored by TLC and then concentrated under reduced pressure.
The residue was added water (50.0&#x02009;ml) and extracted with dichloromethane. The organic
layer was washed with saturated NaCl and dried over anhydrous
Na<sub>2</sub>SO<sub>4</sub>. Then it can be purified by chromatography on silica eluting
with a gradient of methanol/dichloromethane (1:50) to obtain the compounds
<bold>5a&#x02013;5t</bold> as white solids.</p><sec id="s0008"><label>2.5.1.</label><title>Ethyl 5-benzyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxylate
(5g)</title><p>Yield: 58.9%, m.p. 157&#x02013;159&#x02009;&#x000b0;C. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300&#x02009;MHz)
<italic>&#x003b4;</italic>: 1.57 (t, 3H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, &#x02013;CH<sub>3</sub>), 4.67
(q, 2H, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, &#x02013;O&#x02013;CH<sub>2</sub>&#x02013;C), 5.63 (s, 2H,
&#x02013;CH<sub>2</sub>&#x02013;), 7.32&#x02013;7.46 (m, 8H, Ar-H), 8.61 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.3&#x02009;Hz,
Ar-H).</p></sec></sec><sec id="s0009"><label>2.6</label><title>General procedure for the synthesis of compound (6a&#x02013;6t)</title><p>To a stirred solution of compound <bold>5a&#x02013;5t</bold> (2 mm0l) in MeOH (10&#x02009;ml) and
ammonium hydroxide (10&#x02009;ml) was added. The reaction mixture was stirred at room temperature
for 2&#x02009;h. The mixture was filtered and then washed with MeOH to give crude product. The
resulting solid residue was purified by silica column chromatography
(CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 30:1) to give compounds <bold>6a&#x02013;6t</bold> as pale
white solids.</p><sec id="s0010"><label>2.6.1.</label><title>5-butyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6a)</title><p>Yield: 46.4%, m.p. 262&#x02013;264&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3314, 3180, 1693 (C=O), 1665
(C=O). <sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 0.95 (t,
<italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz, 3H, &#x02013;CH<sub>3</sub>), 1.40&#x02013;1.47 (m, 2H,
&#x02013;CH<sub>2</sub>&#x02013;), 1.61&#x02013;1.71 (m, 2H, &#x02013;CH<sub>2</sub>&#x02013;), 4.29 (t,
<italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, 2H, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.41 (t,
<italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H, Ar-H), 7.60 (t, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H, Ar-H),
7.70 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, 1H, Ar-H), 8.47 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz,
1H, Ar-H), 8.49, 8.88 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 14.20, 19.98, 29.28, 41.79, 117.10, 119.38,
121.13, 123.74, 129.09, 129.95, 144.31, 146.44, 151.81, 160.53. ESI-HRMS calculated for
C<sub>14</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 286.1299; found: 286.1302.</p></sec><sec id="s0011"><label>2.6.2.</label><title>5-pentyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6b)</title><p>Yield: 56.7%, m.p. 232&#x02013;234&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3354, 3162, 1680 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 0.88 (t,
<italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, 3H, &#x02013;CH<sub>3</sub>), 1.38 (s, 4H,
&#x02013;(CH<sub>2</sub>)<sub>2</sub>&#x02013;), 1.68 (s, 2H, &#x02013;CH<sub>2</sub>&#x02013;), 4.28 (t,
<italic>J</italic>&#x02009;=&#x02009;6.2&#x02009;Hz, 2H, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.40 (t,
<italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H, Ar-H), 7.60 (t, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H, Ar-H),
7.70 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, 1H, Ar-H), 8.47 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz,
1H, Ar-H), 8.49, 8.88 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C NMR (75&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 14.35, 22.39, 26.88, 28.81, 42.00, 117.09,
119.39, 121.13, 123.75, 129.11, 129.96, 144.32, 146.45, 151.81, 160.53. ESI-HRMS
calculated for C<sub>15</sub>H<sub>18</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 300.1455; found: 300.1458.</p></sec><sec id="s0012"><label>2.6.3.</label><title>5-hexyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6c)</title><p>Yield: 36.4%, m.p. 239&#x02013;241&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3360, 3169, 1725 (C=O), 1683
(C=O). <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>, 300&#x02009;MHz) <italic>&#x003b4;</italic>: 0.88 (t, 3H,
<italic>J</italic>&#x02009;=&#x02009;6.3&#x02009;Hz, &#x02013;CH<sub>3</sub>) 1.30&#x02013;1.42 (m, 6H,
&#x02013;(CH<sub>2</sub>)<sub>3</sub>&#x02013;), 1.61&#x02013;1.72 (m, 2H, &#x02013;CH<sub>2</sub>&#x02013;), 4.27 (t, 2H,
<italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.40 (t,
<italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H, Ar-H), 7.59 (t, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H, Ar-H),
7.71 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, 1H, Ar-H), 8.46 (d, 1H,
<italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, Ar-H), 8.50, 8.89 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C
NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 14.35, 22.49, 26.33, 27.14, 31.44,
42.04, 117.03, 119.39, 121.11, 123.71, 129.08, 129.92, 144.29, 146.46, 151.77, 160.50.
ESI-HRMS calculated for
C<sub>16</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 314.1612; found: 314.1161.</p></sec><sec id="s0013"><label>2.6.4.</label><title>5-heptyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6d)</title><p>Yield: 32.2%, m.p. 231&#x02013;233&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3349, 3156, 1682 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 0.85 (s, 3H,
<italic>J</italic>&#x02009;=&#x02009;6.3&#x02009;Hz, &#x02013;CH<sub>3</sub>), 1.26&#x02013;1.38 (m, 8H,
&#x02013;(CH<sub>2</sub>)<sub>4</sub>&#x02013;), 1.67 (s, 2H, &#x02013;CH<sub>2</sub>&#x02013;), 4.27 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.39&#x02013;7.70 (m, 3H, Ar-H), 8.46 (s, 1H, Ar-H), 8.49, 8.89 (s, 2H,
&#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>:
14.41, 22.51, 26.64, 27.19, 28.92, 31.68, 42.03, 117.06, 119.39, 121.10, 123.72, 129.08,
129.92, 144.31, 146.45, 151.78, 160.51. ESI-HRMS calculated for
C<sub>17</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 328.1768; found: 328.1765.</p></sec><sec id="s0014"><label>2.6.5.</label><title>5-octyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6e)</title><p>Yield: 30.1%, m.p. 230&#x02013;232&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3351, 3156, 1682 (C=O),
1673(C=O). <sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 0.85 (s,
3H, <italic>J</italic>&#x02009;=&#x02009;6.3&#x02009;Hz, &#x02013;CH<sub>3</sub>), 1.24 (s, 8H,
&#x02013;(CH<sub>2</sub>)<sub>4</sub>&#x02013;), 1.40 (s, 2H, &#x02013;CH<sub>2</sub>&#x02013;), 1.58&#x02013;1.74 (m, 2H,
&#x02013;CH<sub>2</sub>&#x02013;) 4.27 (t, 2H, <italic>J</italic>&#x02009;=&#x02009;6.6&#x02009;Hz, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.39
(t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ar-H), 7.58 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz,
Ar-H), 7.69 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, Ar-H), 8.47 (t, 1H,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, Ar-H), 8.49, 8.89 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C
NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 14.40, 22.54, 26.67, 27.17, 29.09,
29.21, 31.69, 42.03, 117.07, 119.40, 121.12, 123.72, 129.09, 129.93, 144.31, 146.45,
151.78, 160.51. ESI-HRMS calculated for
C<sub>18</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 342.1925; found: 342.1922.</p></sec><sec id="s0015"><label>2.6.6.</label><title>5-nonyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6f)</title><p>Yield: 30.1%, m.p. 236&#x02013;238&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3353, 3155, 1682 (C=O),
1671(C=O). <sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 0.84 (m,
3H, <italic>J</italic>&#x02009;=&#x02009;6.3&#x02009;Hz, &#x02013;CH<sub>3</sub>), 1.24&#x02013;1.40 (m, 12H,
&#x02013;(CH<sub>2</sub>)<sub>6</sub>&#x02013;), 1.58&#x02013;1.74 (m, 2H, &#x02013;CH<sub>2</sub>&#x02013;), 4.26 (t, 2H,
<italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.39 (t, 1H,
<italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ar-H), 7.58 (t, 1H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ar-H),
7.69 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, Ar-H), 8.47 (t, 1H,
<italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, Ar-H), 8.49, 8.89 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C
NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 14.41, 22.55, 26.66, 27.17, 29.11,
29.26, 29.36, 31.74, 42.02, 117.07, 119.40, 121.12, 123.72, 129.08, 129.93, 144.31,
146.45, 151.78, 160.51. ESI-HRMS calculated for
C<sub>19</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 356.2081; found: 356.2078.</p></sec><sec id="s0016"><label>2.6.7.</label><title>5-benzyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide
(6g)</title><p>Yield: 35.8%, m.p. 268&#x02013;270&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3345, 3157, 1682 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.57 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.36&#x02013;7.45 (m, 8H, Ar-H), 8.52 (s, 2H, Ar-H, &#x02013;NH), 8.92 (s, 1H,
&#x02013;NH). <sup>13&#x02009;</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 45.42,
117.56, 119.35, 121.38, 123.96, 127.06 (2&#x02009;C), 127.77, 128.85, 129.12 (2&#x02009;C), 130.10,
136.07, 144.59, 146.60, 152.54, 160.53. ESI-HRMS calculated for
C<sub>17</sub>H<sub>14</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 320.1142; found: 320.1140.</p></sec><sec id="s0017"><label>2.6.8.</label><title>5-(2-fluorobenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6h)</title><p>Yield: 28.2%, m.p. 273&#x02013;275&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3340, 3165, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.56 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.08&#x02013;7.50 (m, 7H, Ar-H), 8.54 (m, 2H, Ar-H, &#x02013;NH), 8.95 (s, 1H,
&#x02013;NH). <sup>13&#x02009;</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 44.05, 115.90
(d, <italic>J</italic>&#x02009;=&#x02009;20.8&#x02009;Hz), 117.11, 119.42, 121.45, 122.81 (d,
<italic>J</italic>&#x02009;=&#x02009;14.0&#x02009;Hz), 124.09, 125.10 (d, <italic>J</italic>&#x02009;=&#x02009;2.5&#x02009;Hz), 128.60
(d, <italic>J</italic>&#x02009;=&#x02009;3.5&#x02009;Hz), 129.01, 129.88 (d, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz),
130.08, 144.58, 146.60, 152.50, 160.33 (d, <italic>J</italic>&#x02009;=&#x02009;242.9&#x02009;Hz), 160.50.
ESI-HRMS calculated for
C<sub>17</sub>H<sub>13</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 338.1048; found: 338.1044.</p></sec><sec id="s0018"><label>2.6.9.</label><title>5&#x02013;(3-fluorobenzyl)-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-
carboxamide (6i)</title><p>Yield: 32.4%, m.p. 276&#x02013;278&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3342, 3155, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.57 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.10 (t, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.25 (t,
<italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, 2H, Ar-H), 7.35&#x02013;7.49 (m, 4H, Ar-H), 8.51 (s, 1H, Ar-H),
8.54, 8.93 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic>: 45.09, 114.17 (d, <italic>J</italic>&#x02009;=&#x02009;38.6&#x02009;Hz), 114.46 (d,
<italic>J</italic>&#x02009;=&#x02009;37.3&#x02009;Hz), 117.37, 119.38, 121.53, 123.15, 123.97, 128.84, 130.10,
131.1 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz), 139.12 (d, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz), 144.76,
146.55, 152.65, 160.54, 162.93 (d, <italic>J</italic>&#x02009;=&#x02009;242.1&#x02009;Hz). ESI-HRMS calculated
for C<sub>17</sub>H<sub>13</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 338.1048; found: 338.1047.</p></sec><sec id="s0019"><label>2.6.10.</label><title>5-(4-fluorobenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6j)</title><p>Yield: 25.7%, m.p. 274&#x02013;276&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3342, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.54 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.16 (t, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 2H, Ar-H), 7.35-8.46 (m,
5H, Ar-H), 8.50 (s, 1H, Ar-H), 8.52, 8.91 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR
(75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 44.79, 115.88 (d,
<italic>J</italic>&#x02009;=&#x02009;21.4&#x02009;Hz, 2&#x02009;C), 117.46, 119.37, 121.44, 123.97, 128.86, 129.27 (d,
<italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, 2&#x02009;C), 130.04, 132.24 (d, <italic>J</italic>&#x02009;=&#x02009;2.7&#x02009;Hz),
144.64, 146.57, 152.57, 160.52. 161.87 (d, <italic>J</italic>&#x02009;=&#x02009;241.7&#x02009;Hz), ESI-HRMS
calculated for C<sub>17</sub>H<sub>13</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 338.1048; found: 338.1045.</p></sec><sec id="s0020"><label>2.6.11.</label><title>5-(2-chlorobenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6k)</title><p>Yield: 31.6%, m.p. 278&#x02013;280&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3334, 3164, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.51 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.14&#x02013;7.23 (m, 3H, Ar-H), 7.32&#x02013;7.51 (m, 3H, Ar-H), 7.59 (d,
<italic>J</italic>&#x02009;=&#x02009;7.9, 1H, Ar-H), 8.53 (s, 1H, Ar-H), 8.56, 8.95 (s, 2H,
&#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>:
44.24, 117.11, 119.45, 121.55, 124.11, 127.81, 127.94, 129.07, 129.58, 130.00, 130.16,
132.09, 132.81, 144.70, 146.60, 152.53, 160.51. ESI-HRMS calculated for
C<sub>17</sub>H<sub>13</sub>ClN<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 354.0752; found: 354.0749.</p></sec><sec id="s0021"><label>2.6.12.</label><title>5-(3-chlorobenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6&#x02009;l)</title><p>Yield: 25.8%, m.p. 269&#x02013;271&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3338, 3158, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.56 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.36&#x02013;7.51 (m, 7H, Ar-H), 8.52 (s, 1H, Ar-H), 8.54, 8.92 (s, 2H,
&#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>:
45.07, 117.36, 119.38, 121.55, 123.98, 125.82, 126.94, 127.80, 128.87, 130.14, 130.93,
133.91, 138.77, 146.54, 152.69, 160.53. ESI-HRMS calculated for
C<sub>17</sub>H<sub>13</sub>ClN<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 354.0752; found: 354.0748.</p></sec><sec id="s0022"><label>2.6.13.</label><title>5-(4-chlorobenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6m)</title><p>Yield: 20.3%, m.p. 282&#x02013;284&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3334, 3158, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.55 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.40 (s, 7H, Ar-H), 8.52 (s, 2H, Ar-H, &#x02013;NH), 8.93 (s, 1H, &#x02013;NH).
<sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 44.88, 117.43,
119.38, 121.44, 124.01, 128.88, 129.03 (2&#x02009;C), 129.10 (2&#x02009;C), 130.02, 132.38, 135.17,
144.64, 146.57, 152.57, 160.52. ESI-HRMS calculated for
C<sub>17</sub>H<sub>13</sub>ClN<sub>5</sub>O<sub>2</sub><sup>+</sup>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 354.0752; found: 354.0750.</p></sec><sec id="s0023"><label>2.6.14.</label><title>5-(3-methoxybenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6n)</title><p>Yield: 38.3%, m.p. 266&#x02013;268&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3314, 3191, 1691 (C=O),
1668(C=O). <sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 3.72 (s,
3H, &#x02013;O&#x02013;CH<sub>3</sub>), 5.52 (s, 2H, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 6.82&#x02013;6.97 (m, 3H, Ar-H), 7.23
(t, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 1H, Ar-H), 7.35-7.47 (m, 3H, Ar-H), 8.50 (s, 1H, Ar-H),
8.52, 8.91 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic>: 45.43, 55.51, 112.87, 113.16, 117.56, 119.03, 119.30, 121.39,
123.94, 128.84, 130.18, 130.26, 137.71, 144.62, 146.58, 152.55, 160.02, 160.53. ESI-HRMS
calculated for C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>O<sub>3</sub>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 350.1248; found: 350.1249.</p></sec><sec id="s0024"><label>2.6.15.</label><title>5-(4-methoxybenzyl)-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-
carboamide (6o)</title><p>Yield: 42.5%, m.p. 264&#x02013;266&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3340, 1682 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 3.71 (s, 3H,
&#x02013;O&#x02013;CH<sub>3</sub>), 5.49 (s, 2H, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 6.89 (s, 2H, Ar-H), 7.33&#x02013;7.48
(m, 5H, Ar-H), 8.51 (s, 2H, Ar-H, &#x02013;NH), 8.91 (s, 1H, &#x02013;NH). <sup>13&#x02009;</sup>C NMR (75&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 44.85, 55.51, 114.51 (2&#x02009;C), 117.60, 119.33,
121.33, 123.91, 127.86, 128.55 (2&#x02009;C), 128.82, 130.04, 144.55, 146.59, 152.49, 158.96,
160.53. ESI-HRMS calculated for C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>O<sub>3</sub>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 350.1248; found: 350.1251.</p></sec><sec id="s0025"><label>2.6.16.</label><title>5-(3,4,5-trimethoxybenzyl)-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxali-
ne-1-carboxamide (6p)</title><p>Yield: 50.6%, m.p. 286&#x02013;288&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3317, 1688 (C=O), 1665(C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 3.62 (s, 3H,
&#x02013;O&#x02013;CH<sub>3</sub>), 3.71 (s, 6H, &#x02013;O&#x02013;CH<sub>3</sub>), 5.46 (s, 2H, &#x02013;N&#x02013;CH<sub>2</sub>&#x02013;),
6.73 (s, 2H, Ar-H), 7.39&#x02013;8.50 (m, 3H, Ar-H), 8.52 (s, 1H, Ar-H), 8.54, 8.92 (s, 2H,
&#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>:
45.96, 56.49 (2&#x02009;C), 60.44, 104.79 (2&#x02009;C), 117.57, 119.28, 121.40, 123.90, 128.84, 130.39,
131.91, 137.16, 144.77, 146.57, 152.69, 153.61 (2&#x02009;C), 160.55. ESI-HRMS calculated for
C<sub>20</sub>H<sub>20</sub>N<sub>5</sub>O<sub>5</sub> ([M&#x02009;+&#x02009;H]<sup>+</sup>):
410.1459; found: 410.1461.</p></sec><sec id="s0026"><label>2.6.17.</label><title>5-(2,4-dichlorobenzyl)-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-
1-carboxamide (6q)</title><p>Yield: 26.3%, m.p. 266&#x02013;268&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3342, 3160, 1682 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.47 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.21&#x02013;7.27 (m, 3H, Ar-H), 7.40&#x02013;7.48 (m, 2H, Ar-H), 7.77 (s, 1H,
Ar-H), 8.53 (s, 1H, Ar-H), 8.56, 8.96 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR
(75&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 44.01, 117.06, 119.46, 121.59, 124.15,
127.98, 129.08, 129.29, 129.50, 130.09, 132.17, 133.13, 133.26, 144.73, 146.59, 152.55,
160.49. ESI-HRMS calculated for
C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 388.0363; found: 388.0367.</p></sec><sec id="s0027"><label>2.6.18.</label><title>5-(3-(Trifluoromethyl)benzyl)-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinox-
aline-1-carboxamide (6r)</title><p>Yield: 36.7%, m.p. 262&#x02013;264&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3331, 3165, 1685 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.65 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.35&#x02013;7.50 (m, 3H, Ar-H), 7.56 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz,
1H, Ar-H), 7.66 (t, <italic>J</italic>&#x02009;=&#x02009;7.0&#x02009;Hz, 2H, Ar-H), 7.85 (s, 1H, Ar-H), 8.52 (s,
1H, Ar-H), 8.55, 8.93 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz,
DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 45.28, 117.29, 119.42, 121.55, 122.82, 124.01,
124.14, 124.57 (d, <italic>J</italic>&#x02009;=&#x02009;4.4&#x02009;Hz), 128.03 (d,
<italic>J</italic>&#x02009;=&#x02009;240.5&#x02009;Hz), 128.89, 129.84 (d, <italic>J</italic>&#x02009;=&#x02009;31.7&#x02009;Hz), 130.14
(d, <italic>J</italic>&#x02009;=&#x02009;6.1&#x02009;Hz), 131.14, 137.76, 144.81, 146.56, 152.76, 160.54.
ESI-HRMS calculated for
C<sub>18</sub>H<sub>13</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 388.1016; found: 388.1018.</p></sec><sec id="s0028"><label>2.6.19.</label><title>5-(4-nitrobenzyl)-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carb-
oxamide (6&#x02009;s)</title><p>Yield: 25.1%, m.p. 273&#x02013;275&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3465, 3311, 1674 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.70 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.36&#x02013;7.48 (m, 3H, Ar-H), 7.68 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz,
2H, Ar-H), 8.18 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, 2H, Ar-H), 8.52 (s, 1H, Ar-H), 8.55,
8.96 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic>: 45.27, 117.29, 119.47, 121.54, 124.15, 128.37 (3&#x02009;C), 128.94 (2&#x02009;C),
130.02, 144.18, 144.71, 146.60, 147.28, 152.65, 160.50. ESI-HRMS calculated for
C<sub>17</sub>H<sub>13</sub>N<sub>6</sub>O<sub>4</sub> ([M&#x02009;+&#x02009;H]<sup>+</sup>):
365.0993; found: 365.0996.</p></sec><sec id="s0029"><label>2.6.20.</label><title>5-(4-cyanobenzyl)-4-oxo-4,5-dihydro-[1, 2,
4]triazolo[4,3-a]quinoxaline-1-carboxamide (6t)</title><p>Yield: 23.6%, m.p. 298&#x02013;300&#x02009;&#x000b0;C. IR (KBr) cm<sup>&#x02212;1</sup>: 3440, 3194, 1680 (C=O).
<sup>1</sup>H-NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>) <italic>&#x003b4;</italic>: 5.65 (s, 2H,
&#x02013;N&#x02013;CH<sub>2</sub>&#x02013;), 7.38&#x02013;7.46 (m, 3H, Ar-H), 7.60 (d, <italic>J</italic>&#x02009;=&#x02009;7. 3&#x02009;Hz,
2H, Ar-H), 7.82 (d, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, 2H, Ar-H), 8.52 (s, 1H, Ar-H), 8.54,
8.94 (s, 2H, &#x02013;NH<sub>2</sub>). <sup>13&#x02009;</sup>C-NMR (75&#x02009;MHz, DMSO-d<sub>6</sub>)
<italic>&#x003b4;</italic>: 45.38, 110.60, 117.28, 119.19, 119.45, 121.55, 124.07, 128.10
(2&#x02009;C), 128.91, 130.05, 132.99 (2&#x02009;C), 142.05, 144.74, 146.58, 152.66, 160.51. ESI-HRMS
calculated for C<sub>18</sub>H<sub>13</sub>N<sub>6</sub>O<sub>2</sub>
([M&#x02009;+&#x02009;H]<sup>+</sup>): 345.1095; found: 345.1097.</p></sec></sec><sec id="s0030"><label>2.7.</label><title>Cell culture and sample treatment</title><p>The RAW 264.7 mouse macrophage cell line was obtained from the China Cell Line Bank
(Beijing, China). Cells were cultured in complete medium (DMEM supplemented with 10%
heat-inactivated FBS, 3&#x02009;mM glutamine and antibiotics (100&#x02009;U/mL penicillin and 100&#x02009;U/mL
streptomycin)) at 37&#x02009;&#x000b0;C in a humidified incubator containing 5% CO<sub>2</sub> and 95%
air. Cells were treated with various concentrations of synthesised compounds for 30&#x02009;min
followed by stimulation with LPS (1&#x02009;&#x000b5;g/L).</p></sec><sec id="s0031"><label>2.8.</label><title>MTT assay for cell viability</title><p>Cell viability studies induced by synthesised compounds were evaluated by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. RAW264.7
macrophages were seeded in 96-well plates at a density of 5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL in
complete medium and incubated for 24&#x02009;h (100&#x02009;&#x000b5;L/well). Then the cells were treated with
different concentrations of synthesised compounds for 24&#x02009;h. 150&#x02009;&#x000b5;L MTT (5&#x02009;g/L in PBS) was
added to each well and the cells were further incubated for 4&#x02009;h. The supernatant was
removed and the cells were lysed with 150&#x02009;&#x000b5;L/well DMSO. The optical density was measured
at 570&#x02009;nm on a microplate reader (Thermo Scientific, MA, USA).</p></sec><sec id="s0032"><label>2.9.</label><title>Assay for NO production</title><p>Nitrite, a stable product of nitric oxide, was used to assess NO production. To study the
effects of the isolated compounds on NO production, RAW264.7 cells were plated at
1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well in a 96-well microplate and incubated overnight. The cells
were pre-treated with various concentrations of the test compounds (3, 7.5, 10, 15, 30 or
100&#x02009;&#x000b5;M) and further co-cultured with 1&#x02009;&#x000b5;g/mL LPS for 24&#x02009;h. Un-pre-treated and
un-stimulated RAW 264.7 cells were conducted as the blank control group. At different time
points, the supernatant (50&#x02009;&#x000b5;L) was assayed with NO assay kit. The culture supernatant
(50&#x02009;&#x000b5;L) was mixed with an equal volume of the Griess reagent (1% sulphanilamide, 0.1%
N-[1-naphthy] ethylenediamine dihydrochloride) and NO production were determined at 540&#x02009;nm
with an ELISAplate reader.</p></sec><sec id="s0033"><label>2.10.</label><title>Cytokine production assay</title><p>RAW264.7 cells were seeded at 3&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well in a 48-well microplate and
incubated overnight.The cells were pre-treated with the different concentrations of the
test compunds (3, 7.5, 10 or 30&#x02009;&#x000b5;M) for 30&#x02009;min before the stimulation with LPS (1&#x02009;&#x000b5;g/mL).
According to the protocol of the manufacturer, supernatants were harvested at the 24th
hour for the assay of TNF-&#x003b1; or IL-6 with ELISA kits (BD Biosciences, San Diego, CA, USA).
Briefly, 100&#x02009;&#x000b5;L of biotinylated antibody reagent and the culture supernatants were added
to anti-mouse TNF-&#x003b1; or IL-6 precoated 96-well plates, and the plates were incubated for
2&#x02009;h at RT. The plate was washed with a washing buffer and subsequently incubated with
100&#x02009;&#x000b5;L of the streptavidin-HRP solution for 1&#x02009;h at RT. The plate was washed, and incubated
with 100&#x02009;&#x000b5;L of TMB substrate solution for 30&#x02009;min at RT in the dark. The reaction was
stopped by adding 50&#x02009;&#x000b5;L of stop solution, and then the absorbance was measured at 450&#x02009;nm
by a plate reader. A standard curve was produced for each assay plate using serially
diluted recombinant IL-6.</p></sec><sec id="s0034"><label>2.11.</label><title>Western blot analysis</title><p>RAW 264.7 cells (5&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well) plated onto 6-well plates were incubated
for 24&#x02009;h and treated with 7.5, 15.0 or 30.0&#x02009;&#x000b5;M of compound <bold>6p</bold> for 30&#x02009;min and
then stimulated with 1&#x02009;&#x000b5;g/L of LPS for 24&#x02009;h. The cells were collected and washed three
times with ice-cold PBS. The cells were treated with a cell lysis buffer [50&#x02009;mM Tris (pH
7.6), 150&#x02009;mM NaCl, 5&#x02009;mM EDTA (pH 8.0), 0.6% NP-40, 1&#x02009;mM Na<sub>3</sub>VO<sub>4</sub>,
20&#x02009;mM &#x003b2;-glycerophosphate, 1&#x02009;mM phenylmethylsulfonyl fluoride, 2&#x02009;mM p-nitrophenyl
phosphate, and 1:25 Complete Mini Protease Inhibitor cocktail (Boehringer,
Mannheim,Germany)] and kept on ice for 30&#x02009;min. The cell lysates were centrifuged (12,000&#x02009;g
at 4&#x02009;&#x000b0;C) for 5&#x02009;min to obtain a cytosolic fraction. The protein concentration was
determined by BCA protein assay kit (Beyotime, Haimen, China). Aliquots of the lysates
were separated on 10% sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis
(PAGE) and then electro blotted onto a polyvinylidene difluoride (PVDF) membrane. The
blots were blocked with 5% (w/v) non-fat dry milk for 2&#x02009;h at 37&#x02009;&#x000b0;C, followed by incubation
with specific primary antibody at 4&#x02009;&#x000b0;C overnight. Blots were washed with Tween
20/Tris-buffered saline [TTBS, 20&#x02009;mM Tris&#x02013;HCl buffer, pH 7.6, containing 137&#x02009;mM NaCl and
0.05% (vol/vol) Tween 20] and incubated with a peroxidase-conjugated secondary antibody
for 1&#x02009;h. Blots were again washed with TTBS and the immune active proteins were detected
using ECL plus (Thermo, USA). All Western blot analyses were carried out at least three
times. Results are expressed as the relative ratio of the specific band compared with the
internal reference.</p></sec><sec id="s0035"><label>2.12.</label><title>In vivo anti-inflammatory activities determination</title><p>The animal procedures were in strict accordance with the National Institutes of Healthy
Guidelines for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised
1996) and were approved by the Institutional Animal Care and Utilisation Committee of
Yanbian University. Male albino rats weighing 280&#x02013;300 gwere obtained from Animal
Department of Yanbian University . They were kept in the animal house under standard
condition of light and temperature with free access to food and water. The animals were
randomly divided into five groups (control, <bold>D1</bold>, <bold>6p</bold>, ibuprofen
and celecoxib group) The groups with <bold>D1</bold>, <bold>6p</bold>, ibuprofen and
celecoxib were administered oral administration (p.o.) 25&#x02009;mg/kg in a vehicle of 0.5%
methylcellulose, respectively. The negative control group was treated with the same
vehicle (0.5% methylcellulose). A solution of carrageenan (0.1&#x02009;ml, 1.0% w/v in 0.9% of
normal saline) was injected into the subplanter region of the left hind paw under light
ether anaesthesia 1&#x02009;h after oral administration (p.o.) of the test compound (at a dose
level of 25&#x02009;mg/kg body weight). The paw volume was measured at hourly interval for 5&#x02009;h (0,
1, 3 and 5&#x02009;h) and the percent inhibition of oedema was calculated using formula:
<disp-formula id="M0001"><alternatives><graphic xlink:href="IENZ_A_1680658_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d1e2282"><mml:mi>%</mml:mi><mml:mtext>Inhibition</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>Vt</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>Vo</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mtext>control</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>Vt</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>Vo</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mtext>tested</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>compound</mml:mtext><mml:mo>&#x02003;</mml:mo><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>Vt</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>Vo</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mtext>control</mml:mtext><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:math></alternatives></disp-formula>
where,<list list-type="simple"><list-item><p>Vo&#x02009;=&#x02009;volume of oedema at zero time interval.</p></list-item><list-item><p>Vt&#x02009;=&#x02009;volume of oedema at specific time interval.</p></list-item></list></p></sec><sec id="s0036"><label>2.13.</label><title>Ulcerogenic effect</title><p>The lead compound <bold>D1</bold> and the newly synthesised compound <bold>6p</bold> were
subjected to <italic>in vivo</italic> testing to measure their ulcerogenic effect in
comparison to celecoxib and ibuprofen. Male albino rats (220&#x02013;250&#x02009;g) divided into 5 groups
(control, <bold>D1</bold>, <bold>6p</bold>, ibuprofen and celecoxib group) of five rats
each. The groups with <bold>D1</bold>, <bold>6p</bold>, ibuprofen, and celecoxib were
administered oral administration (p.o.) 25&#x02009;mg/kg in a vehicle of 0.5% methylcellulose,
respectively. The negative control group was treated with the same vehicle (0.5%
methylcellulose). All groups were orally administered once a day for three consecutive
days. Animals were sacrificed by diethyl ether 6&#x02009;h after the last dose and the stomach was
removed. An opening at the greater curvature was made and the stomach was cleaned by
washing with cold saline and inspected with a three-time magnifying lens for any evidence
of hyperaemia, haemorrhage, definite haemorrhagic erosion, or ulcer. An arbitrary scale
was used to calculate the ulcer index which indicates the severity of the stomach lesions
The % ulceration for each group was calculated as follows: % Ulceration&#x02009;=&#x02009;Number of
animals bearing ulcer in a group/Total number of animals in the same group &#x000d7;100.</p></sec></sec><sec id="s0037"><label>3.</label><title>Results and discussion</title><sec id="s0038"><label>3.1.</label><title>Chemistry</title><p>The steps involved in the preparation of the target compounds <bold>6a&#x02013;6t</bold> are
outlined in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>. The starting material,
<italic>o</italic>-phenylenediamine (<bold>1</bold>), was reacted with oxalic acid in
10% hydrochloric acid to obtain
quinoxaline-2,3(1<italic>H</italic>,4<italic>H</italic>)-dione (<bold>2</bold>) (a white
needle solid). Unlike in the previous synthesis method<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>, diethyl oxalate was replaced with hydrochloric acid solution in
oxalic acid, and the white needle-like solid was directly precipitated after the reaction,
which not only shortened the reaction time but also made the post-treatment easier.
Compound <bold>2</bold> was then reacted with hydrazine hydrate to obtain compound
<bold>3</bold> (3-hydrazinylquinoxalin-2(1<italic>H</italic>)-one) with only one
carbonyl group substituted<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>, and
compound <bold>4</bold> was prepared by cyclizing compound <bold>3</bold> with diethyl
oxalate. Finally, compound <bold>4</bold> was reacted with appropriate brominated alkanes
and substituted with chlorobenzyl in the presence of K<sub>2</sub>CO<sub>3</sub> to yield
compounds <bold>5a&#x02013;5t,</bold> which were reacted further with
NH<sub>3</sub>&#x000b7;H<sub>2</sub>O in methanol to obtain the target compounds
<bold>6a&#x02013;6t</bold><xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>. The
synthesised compounds were analysed by <sup>1</sup>H-NMR, <sup>13&#x02009;</sup>C-NMR, and
HRMS.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Reagents and conditions: (a) oxalic acid, HCl/H<sub>2</sub>O, 100&#x02009;&#x000b0;C, 2&#x02009;h; (b)
Hydrazine hydrate, 100&#x02009;&#x000b0;C, 2&#x02009;h; (c) Diethyl oxalate, reflux, 3&#x02009;h; (d) RX,
K<sub>2</sub>CO<sub>3</sub>, DMF, 60&#x02009;&#x000b0;C, 3&#x02009;h; (e) NH<sub>3</sub>&#x000b7;H<sub>2</sub>O,
methanol, r.t., 2&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1680658_SCH0001_B"/></fig></sec><sec id="s0039"><label>3.2.</label><title>Cytotoxicity of the target compounds 6a&#x02013;<italic>6t</italic></title><p>To investigate whether the anti-inflammatory activities of the target compounds
<bold>6a&#x02013;6t</bold> were related to cell viability, their cytotoxic effects were
evaluated by MTT assay in RAW264.7 cells<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. As shown in <xref rid="t0001" ref-type="table">Table 1</xref>,
except for compounds <bold>6i</bold> and <bold>6j</bold>, the other compounds at
concentrations of 10 or 30&#x02009;&#x000b5;M showed no obvious cytotoxic effects in RAW264.7 cells, and
the relative cell viabilities of the treated cells were more than 80%. Thus, 10&#x02009;&#x000b5;M
concentration was chosen for subsequent experiments.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Effect of compounds <bold>6a&#x02013;6t</bold> on the viability of RAW264.7 cells.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Compound</th><th rowspan="2" align="center">R</th><th colspan="2" align="center">Cell viability
(%)<hr/></th></tr><tr><th align="center">30&#x02009;&#x003bc;M</th><th align="center">10&#x02009;&#x003bc;M</th></tr></thead><tbody valign="top"><tr><td align="left">blank</td><td align="center">&#x02013;</td><td align="char" char=".">100</td><td align="center">100</td></tr><tr><td align="left">LPS</td><td align="center">&#x02013;</td><td align="char" char=".">98.60&#x02009;&#x000b1;&#x02009;2.12<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref></td><td align="center">NT<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></td></tr><tr><td align="left"><bold>D1</bold></td><td align="center">&#x02013;</td><td align="char" char=".">96.30&#x02009;&#x000b1;&#x02009;1.72</td><td align="center">NT</td></tr><tr><td align="left"><bold>6a</bold></td><td align="center"><italic>n</italic>-C<sub>4</sub>H<sub>9</sub></td><td align="char" char=".">92.33&#x02009;&#x000b1;&#x02009;1.53</td><td align="center">NT</td></tr><tr><td align="left"><bold>6b</bold></td><td align="center"><italic>n</italic>-C<sub>5</sub>H<sub>11</sub></td><td align="char" char=".">97.95&#x02009;&#x000b1;&#x02009;1.1</td><td align="center">NT</td></tr><tr><td align="left"><bold>6c</bold></td><td align="center"><italic>n</italic>-C<sub>6</sub>H<sub>13</sub></td><td align="char" char=".">99.11&#x02009;&#x000b1;&#x02009;0.69</td><td align="center">NT</td></tr><tr><td align="left"><bold>6d</bold></td><td align="center"><italic>n</italic>-C<sub>7</sub>H<sub>15</sub></td><td align="char" char=".">81.00&#x02009;&#x000b1;&#x02009;1.10</td><td align="center">NT</td></tr><tr><td align="left"><bold>6e</bold></td><td align="center"><italic>n</italic>-C<sub>8</sub>H<sub>17</sub></td><td align="char" char=".">99.51&#x02009;&#x000b1;&#x02009;2.30</td><td align="center">NT</td></tr><tr><td align="left"><bold>6f</bold></td><td align="center"><italic>n</italic>-C<sub>9</sub>H<sub>19</sub></td><td align="char" char=".">60.00&#x02009;&#x000b1;&#x02009;3.40</td><td align="center">99.15&#x02009;&#x000b1;&#x02009;1.65</td></tr><tr><td align="left"><bold>6g</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td><td align="char" char=".">85.02&#x02009;&#x000b1;&#x02009;1.00</td><td align="center">NT</td></tr><tr><td align="left"><bold>6h</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>o</italic>-F)</td><td align="char" char=".">66.67&#x02009;&#x000b1;&#x02009;1.33</td><td align="center">98.49&#x02009;&#x000b1;&#x02009;1.76</td></tr><tr><td align="left"><bold>6i</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>m</italic>-F)</td><td align="char" char=".">59.33&#x02009;&#x000b1;&#x02009;2.52</td><td align="center">99.46&#x02009;&#x000b1;&#x02009;4.17</td></tr><tr><td align="left"><bold>6j</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>p</italic>-F)</td><td align="char" char=".">48.00&#x02009;&#x000b1;&#x02009;3.00</td><td align="center">73.45&#x02009;&#x000b1;&#x02009;2.27</td></tr><tr><td align="left"><bold>6k</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>o</italic>-Cl)</td><td align="char" char=".">46.33&#x02009;&#x000b1;&#x02009;2.89</td><td align="center">74.56&#x02009;&#x000b1;&#x02009;1.38</td></tr><tr><td align="left"><bold>6l</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>m</italic>-Cl)</td><td align="char" char=".">51.67&#x02009;&#x000b1;&#x02009;2.12</td><td align="center">87.92&#x02009;&#x000b1;&#x02009;5.18</td></tr><tr><td align="left"><bold>6m</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>p</italic>-Cl)</td><td align="char" char=".">44.67&#x02009;&#x000b1;&#x02009;3.06</td><td align="center">82.18&#x02009;&#x000b1;&#x02009;1.74</td></tr><tr><td align="left"><bold>6n</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>m</italic>-OCH<sub>3</sub>)</td><td align="char" char=".">93.33&#x02009;&#x000b1;&#x02009;0.58</td><td align="center">NT</td></tr><tr><td align="left"><bold>6o</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>p</italic>-OCH<sub>3</sub>)</td><td align="char" char=".">80.12&#x02009;&#x000b1;&#x02009;1.00</td><td align="center">NT</td></tr><tr><td align="left"><bold>6p</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>2</sub>(<italic>3</italic>,<italic>4</italic>,<italic>5</italic>-(OCH<sub>3</sub>)<sub>3</sub>)</td><td align="char" char=".">83.67&#x02009;&#x000b1;&#x02009;1.53</td><td align="center">NT</td></tr><tr><td align="left"><bold>6q</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(<italic>2</italic>,<italic>4</italic>-Cl<sub>2</sub>)</td><td align="char" char=".">56.67&#x02009;&#x000b1;&#x02009;1.34</td><td align="center">84.69&#x02009;&#x000b1;&#x02009;6.49</td></tr><tr><td align="left"><bold>6r</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>m</italic>-CF<sub>3</sub>)</td><td align="char" char=".">99.30&#x02009;&#x000b1;&#x02009;0.60</td><td align="center">NT</td></tr><tr><td align="left"><bold>6s</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>p</italic>-NO<sub>2</sub>)</td><td align="char" char=".">80.10&#x02009;&#x000b1;&#x02009;1.34</td><td align="center">NT</td></tr><tr><td align="left"><bold>6t</bold></td><td align="center">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(<italic>p</italic>-CN)</td><td align="char" char=".">90.33&#x02009;&#x000b1;&#x02009;1.21</td><td align="center">NT</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label>a</label><p>LPS (1&#x02009;&#x003bc;g/mL).</p></fn><fn id="TF2"><label>b</label><p>No tested.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s0040"><label>3.3.</label><title>Inhibition of NO production in (LPS)-stimulated RAW264.7 cells and SAR
studies</title><p>High levels of NO are produced in response to LPS (1&#x02009;&#x000b5;g/mL) in the activated RAW264.7
macrophages<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>. Therefore, NO
inhibitors have been identified as good options for the treatment of inflammatory
diseases<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>. The anti-inflammatory
activities of the target compounds <bold>6a&#x02013;6t</bold> were tested based on their ability
to inhibit LPS-induced NO production in RAW264.7 macrophages. As shown in <xref ref-type="fig" rid="F0001">Figure 1(A)</xref>, LPS treatment caused a significant
increase in NO release compared to that in untreated controls, which was inhibited after
treatment with the synthetic derivatives in RAW264.7 cells. Among them, compounds
<bold>6b</bold>, <bold>6d</bold>, <bold>6e</bold>, <bold>6f</bold>, <bold>6i</bold>,
<bold>6j</bold>, <bold>6n</bold>, <bold>6o</bold>, <bold>6p</bold>, <bold>6r,</bold> and
<bold>6s</bold> exhibited similar or better NO inhibitory activity than the lead
compound <bold>D1</bold>. Compound <bold>6p</bold> (10&#x02009;&#x000b5;M) exhibited the most potent
inhibitory activity (38.82%) and was more potent than <bold>D1</bold> (a 10.31%
inhibition). When the concentration of compound <bold>6p</bold> was reduced to 3&#x02009;&#x000b5;M, it
was still able to significantly inhibit NO production (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001)
(<xref ref-type="fig" rid="F0002">Figure 2(A))</xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>RAW264.7 cells were pre-cultured for 24&#x02009;h, the cells were then treated with the
indicated concentrations of compounds for 30&#x02009;min, and then exposed to 1&#x02009;&#x003bc;g/mL LPS for
24&#x02009;h. The levels of NO in the culture medium were measured with NO assay kit. (A)
Cells were treated with 10&#x02009;&#x003bc;M compounds. Cells were pre-treated with different
concentrations of compound <bold>6p</bold>. NO, TNF-&#x003b1; and IL-6 levels in the medium
were determined with an ELISA kit. (B, C and D). ### <italic>p</italic>&#x02009;&#x0003c;&#x02009;.01, vs.
Control. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01,
***<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001 vs. LPS alone.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1680658_F0002_B"/></fig><p>The following structure-activity relationships (SAR) of the synthetic compounds were
determined: the length of the alkyl chain appeared to have a direct impact on the
anti-inflammatory activity of the 5-alkyl derivatives <bold>6a&#x02013;6f</bold>. As the alkyl
chain length of the derivatives <bold>6a&#x02013;6e</bold> increased, their anti-inflammatory
activities increased, with compound <bold>6e</bold> (n-octyl substitution) being the most
active. When the length of the linear alkyl group reached 9 carbon atoms (compound
<bold>6f</bold>), the anti-inflammatory activity began to decrease. We hypothesised that
the n-octyl-substituted compound, <bold>6e,</bold> has the most favourable exponential
partition coefficient and easily passes through the cell membrane. For the
benzyloxy-substituted derivatives <bold>6g&#x02013;6t</bold>, the type and position of the
substituent on the benzene ring had a significant effect on anti-inflammatory activity.
The activity order was
<italic>3,4,5</italic>-OCH<sub>3</sub>&#x0003e;<italic>m</italic>-OCH<sub>3</sub>&#x0003e;<italic>p</italic>-OCH<sub>3</sub>&#x0003e;<italic>m</italic>-F&#x0003e;<italic>p</italic>-F&#x0003e;<italic>m</italic>-CF<sub>3</sub>&#x0003e;<italic>p</italic>-NO<sub>2</sub>&#x0003e;<italic>p</italic>-CN,
indicating that the electron-donating group exerts a greater effect than the
electron-withdrawing group in increasing the anti-inflammatory activities of these
derivatives.</p></sec><sec id="s0041"><label>3.4.</label><title><italic>Compound 6p inhibited IL-6 and TNF-</italic>&#x003b1; <italic>production in RAW264.7
cells</italic></title><p>Based on the initial screening results of these synthetic derivatives, compound
<bold>6p</bold> was chosen for further assessment of its anti-inflammatory activity in
LPS-induced macrophages. It is well known that the pro-inflammatory mediators IL-6 and
TNF-&#x003b1; play important roles in the development of inflammation-related diseases<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. To measure the effects of compound
<bold>6p</bold> on LPS-induced IL-6 and TNF-&#x003b1; production, RAW264.7 cells were cultured
with LPS (1&#x02009;&#x000b5;g/mL) in the presence of compound <bold>6p</bold> for 24&#x02009;h, and the levels of
IL-6 and TNF-&#x003b1; in the supernatant were determined by ELISA. As shown in <xref ref-type="fig" rid="F0002">Figure 2(B,C)</xref>, LPS stimulation significantly elevated
the production of TNF-&#x003b1; and IL-6. After treatment with compound <bold>6p,</bold> the
LPS-induced increase in IL-6 and TNF-&#x003b1; levels was inhibited in a concentration-dependent
manner. Even at low concentrations (3&#x02009;&#x000b5;M), <bold>6p</bold> significantly inhibited the
production of these two inflammatory factors (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001).</p></sec><sec id="s0042"><label>3.5.</label><title>Compound 6p inhibited the expression of iNOS and COX-2</title><p>The pro-inflammatory mediator NO plays an important role in inflammation-related diseases
and its production is closely related to the modulation of iNOS and COX-2 expression<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Our results show that compound
<bold>6p</bold> can significantly inhibit the production of NO. To establish whether
this inhibitory effect was associated with the reduced expression of iNOS and COX-2 in
LPS-induced RAW 264.7 cells, the levels of these proteins were measured by western
blotting after exposure to LPS for 24&#x02009;h in the presence or absence of compound
<bold>6p</bold> (7.5, 15, and 30&#x02009;&#x000b5;M). Celecoxib (7.5&#x02009;&#x000b5;M) was used as a positive control.
As shown in <xref ref-type="fig" rid="F0003">Figure 3</xref>, LPS (1&#x02009;&#x000b5;g/mL) stimulation
markedly increased COX-2 and iNOS protein expression and compound <bold>6p</bold>
inhibited this response (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001) by 53.44% (COX-2) at 15&#x02009;&#x000b5;M and
39.89% (iNOS) at 30&#x02009;&#x000b5;M, respectively. Moreover, compound <bold>6p</bold> inhibited iNOS
protein expression in LPS-induced cells in a dose-dependent manner. These results suggest
that <bold>6p</bold> exerts its anti-inflammatory activity through inhibiting the
expression of iNOS, and COX-2 by LPS in macrophages.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Compound <bold>6p</bold> inhibited LPS-induced inflammatory response in RAW 264.7
cells. Cells were pre-treated with different concentrations of <bold>6p</bold>
(7.5&#x02013;30&#x02009;&#x000b5;M) and Celecoxib (7.5&#x02009;&#x000b5;M) for 24&#x02009;h. iNOS, COX-2 and GAPDH proteins expression
were detected by Western blot analysis. Total cellular proteins were prepared and
analysed by Western blotting. Results are the mean&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3. ###
<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001, vs. Control. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05,
**<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001 vs. LPS alone.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1680658_F0003_B"/></fig></sec><sec id="s0043"><label>3.6.</label><title>Compound 6p inhibited MAPK signalling activation</title><p>As upstream proteins, phosphorylation of the MAPK family of proteins is closely related
to and plays an important role in the expression of iNOS and COX-2, and the release of
inflammatory factors in LPS-induced inflammatory responses<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. To find the molecular target of compound <bold>6p</bold>
further upstream of the MAPK signalling pathway, the effects of compound <bold>6p</bold>
on the LPS-induced phosphorylation of ERK, JNK, and p38 MAPKs in RAW 264.7 cells were
assessed by western blotting. Celecoxib (7.5&#x02009;&#x000b5;M) was used as positive control. As expected
(<xref ref-type="fig" rid="F0004">Figure 4</xref>), phosphorylation of p38, JNK, and ERK
increased after LPS stimulation. Compound <bold>6p</bold> markedly diminished the
phosphorylation of JNK (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001), ERK (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001)
and p38 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01) MAPKs at 30&#x02009;&#x000b5;M (<xref ref-type="fig" rid="F0004">Figure 4(A&#x02013;C)</xref>). Furthermore, compound <bold>6p</bold> (7.5, 15, and 30&#x02009;&#x000b5;M)
inhibited the LPS-induced phosphorylation of JNK and ERK in a concentration-dependent
manner. These results suggest that the anti-inflammatory effect of compound
<bold>6p</bold> might be associated with the inhibitory effects on the MAPK signalling
pathways.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Compound <bold>6p</bold> inhibited LPS-induced inflammatory response in RAW 264.7
cells. Cells were pre-treated with different concentrations of <bold>6p</bold>
(7.5&#x02013;30&#x02009;&#x000b5;M) and Celecoxib (7.5&#x02009;&#x000b5;M) for 24&#x02009;h. The levels of p-p38/P38, p-ERK/ERK,
p-JNK/JNK and GAPDH proteins, and their phosphorylated forms were analysed using
Western blotting. Total cellular proteins were prepared and analysed by Western
blotting. Results are the mean&#x02009;&#x000b1;&#x02009;SD, <italic>n</italic>&#x02009;=&#x02009;3. ###
<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001, vs. Control. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05,
**<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001 vs. LPS alone.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1680658_F0004_B"/></fig></sec><sec id="s0044"><label>3.7.</label><title>In vivo anti-inflammatory activity</title><p>To evaluate the anti-inflammatory activity of compound <bold>6p</bold>
<italic>in vivo</italic>, a carrageenan-induced mouse paw oedema model was used<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>. Each test compound (lead compound <bold>D1,
6p,</bold> and the positive controls ibuprofen and celecoxib) was administered orally at
a dose of 25&#x02009;mg/kg body weight prior to the induction of inflammation by carrageenan
(0.1&#x02009;ml) injection. The paw volume was measured over 5&#x02009;h (at 0, 1, 3, and 5&#x02009;h) and the
percent inhibition of oedema was calculated (<xref rid="t0002" ref-type="table">Table
2</xref>). Inhibition of paw swelling was the highest in mice 3&#x02009;h after carrageenan
administration by all the tested compounds. It is noteworthy that compound <bold>6p</bold>
displayed anti-inflammatory effects (50.83%) that were significantly greater than those of
the lead compound <bold>D1</bold> (42.81%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;.01) and ibuprofen
(39.30%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;.01), but slightly lesser than those of celecoxib
(58.34%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05) (<xref ref-type="fig" rid="F0005">Figure
5</xref>).</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>The inhibited paw swelling actives of lead compound <bold>D1</bold>, <bold>6p</bold>
and positive control drugs (25&#x02009;mg/kg) in a carrageenan-induced mouse paw oedema model
after 3&#x02009;h of oral administration. **<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01, vs. <bold>D1</bold>;
##<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01, vs. Ibuprofen; $ <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05, vs.
Celecoxib.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1680658_F0005_C"/></fig><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>The anti-inflammatory activity and ulcerogenic activity <italic>in vivo</italic>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Compounds</th><th colspan="3" align="center">% of oedema
inhibition (% mean&#x02009;&#x000b1;&#x02009;SD)<xref ref-type="table-fn" rid="TF3"><sup>a</sup></xref><hr/></th><th rowspan="2" align="center">% ulceration</th></tr><tr><th align="center">1&#x02009;h</th><th align="center">3&#x02009;h</th><th align="center">5&#x02009;h</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>D1</bold></td><td align="char" char=".">38.26&#x02009;&#x000b1;&#x02009;2.82</td><td align="char" char=".">42.81&#x02009;&#x000b1;&#x02009;2.11</td><td align="char" char=".">28.71&#x02009;&#x000b1;&#x02009;2.92</td><td>20</td></tr><tr><td align="left"><bold>6p</bold></td><td align="char" char=".">37.01&#x02009;&#x000b1;&#x02009;8.45</td><td align="char" char=".">50.83&#x02009;&#x000b1;&#x02009;3.47</td><td align="char" char=".">38.24&#x02009;&#x000b1;&#x02009;6.04</td><td>20</td></tr><tr><td align="left"><bold>Ibuprofen</bold></td><td align="char" char=".">31.92&#x02009;&#x000b1;&#x02009;5.76</td><td align="char" char=".">39.30&#x02009;&#x000b1;&#x02009;4.86</td><td align="char" char=".">25.29&#x02009;&#x000b1;&#x02009;3.43</td><td>100</td></tr><tr><td align="left"><bold>Celecoxib</bold></td><td align="char" char=".">48.09&#x02009;&#x000b1;&#x02009;5.33</td><td align="char" char=".">58.34&#x02009;&#x000b1;&#x02009;4.08</td><td align="char" char=".">41.92&#x02009;&#x000b1;&#x02009;2.05</td><td>0</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><label>a</label><p>Values are expressed as the mean&#x02009;&#x000b1;&#x02009;S.D (<italic>n</italic>&#x02009;=&#x02009;4).</p></fn><fn id="TF4"><p>Control: 0.5% sodium CMC solution in distilled water (25&#x02009;ml/kg,
<italic>p.o.</italic>).</p></fn><fn id="TF5"><p>Compounds and positive drugs were administered at a dose of 25&#x02009;mg/kg,
<italic>p.o</italic>. in 0.5% sodium CMC solution.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s0045"><label>3.8.</label><title>Ulcerogenic effect</title><p>In order to evaluate the damage of the synthesised compound to the gastric mucosa, acute
ulcerogenic studies were carried out for the most biologically active synthesised compound
<bold>6p</bold>, lead compound <bold>D1</bold>, ibuprofen and celecoxib as standard was
evaluated using the reference reported procedure<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>. Results are presented in <xref rid="t0002" ref-type="table">Table 2</xref> as % ulceration. The ulceration effect of compound <bold>6p</bold> was
stronger than the selective COX-2 inhibitor celecoxib (no ulceration), which was weaker
than the non-selective COX-2 inhibitor ibuprofen that showed 100% ulceration.</p></sec></sec><sec id="s0046"><label>4.</label><title>Conclusions</title><p>In summary, we designed, synthesised, and characterised a series of
5-alkyl-4-oxo-4,5-dihydro-[1, 2, 4]triazolo[4,3-a]quinoxaline-1-carboxamide derivatives
using by <sup>1</sup>H-NMR, <sup>13&#x02009;</sup>C-NMR and HRMS. All the tested compounds inhibited
LPS-induced NO production in RAW264.7 macrophages. Among them, compound <bold>6p</bold>
exhibited the most significant activity and was more potent than the lead compound
<bold>D1</bold>. Investigation of the mechanisms underlying the anti-inflammatory activity
of compound <bold>6p</bold> showed that it inhibits the expression of iNOS and COX-2 and the
production of NO, TNF-&#x003b1;, and IL-6 by suppressing the LPS-induced MAPK signalling
pathway.</p><p>Furthermore, compound <bold>6p</bold> displayed more prominent anti-inflammatory activity
and weaker ulceration than the positive control ibuprofen in the <italic>in vivo</italic>
acute inflammatory model. These findings indicate that compound <bold>6p</bold> could serve
as a promising anti-inflammatory agent and warrants further studies.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM1222"><caption><title>Supplemental Material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="IENZ_A_1680658_SM1222.pdf" orientation="portrait" id="d37e214" position="anchor"/></supplementary-material></sec></body>
<back><sec id="s0047"><title>Disclosure statement</title><p>The authors declare no conflict of interest.</p></sec>
<ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrero</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>OH</given-names></name>, <name name-style="western"><surname>Andersen</surname><given-names>PS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta
generation</article-title>. <source>Clin Exp Immunol</source>
<year>2007</year>;<volume>147</volume>:<fpage>227</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">17223962</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L-D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Development and mechanism investigation of a new piperlongumine derivative
as a potent anti-inflammatory agent</article-title>. <source>Biochem Pharmacol</source>
<year>2015</year>;<volume>95</volume>:<fpage>156</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">25850000</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duque</surname><given-names>AG</given-names></name>,
<name name-style="western"><surname>Descoteaux</surname><given-names>A</given-names></name></person-group>
<article-title>Macrophage
cytokines: involvement in immunity and infectious diseases</article-title>.
<source>Front Immunol</source>
<year>2014</year>;<volume>5</volume>:<fpage>491</fpage>.<pub-id pub-id-type="pmid">25339958</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bremner</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Heinrich</surname><given-names>M</given-names></name></person-group>
<article-title>Natural
products as targeted modulators of the nuclear factor-&#x003ba;B pathway</article-title>.
<source>J Pharm Pharmacol</source>
<year>2002</year>;<volume>54</volume>:<fpage>453</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">11999122</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grivennikov</surname><given-names>SI</given-names></name>, <name name-style="western"><surname>Greten</surname><given-names>FR</given-names></name>, <name name-style="western"><surname>Karin</surname><given-names>M</given-names></name></person-group>
<article-title>Immunity,
inflammation, and cancer</article-title>. <source>Cell</source>
<year>2010</year>;<volume>140</volume>:<fpage>883</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">20303878</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>RS</given-names></name>,
<name name-style="western"><surname>Antonisamy</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Almansour</surname><given-names>AI</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Functionalized spirooxindole-indolizine hybrids: stereoselective green
synthesis and evaluation of anti-inflammatory effect involving TNF-&#x003b1; and nitrite
inhibition</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>152</volume>:<fpage>417</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">29751235</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>XX</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of new ent-labdane diterpene derivatives from andrographolide and
evaluation of their anti-inflammatory activities</article-title>. <source>Eur J Med
Chem</source>
<year>2019</year>;<volume>162</volume>:<fpage>70</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30419492</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>XT</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>ZY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Magnesium isoglycyrrhi- zinate suppresses LPS-induced inflammation and
oxidative stress through inhibit- ing NF-&#x003ba;B and MAPKpathways in RAW264.7
cells</article-title>. <source>Bioorg Med Chem</source>
<year>2019</year>;<volume>27</volume>:<fpage>516</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">30617018</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>CQ</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>YY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ginkgo biloba sarcotesta polysaccharide inhibits inflammatory responses
through suppressing both NF-&#x003ba;B and MAPK signaling pathway</article-title>. <source>J Sci
Food Agric</source>
<year>2019</year>;<volume>99</volume>:<fpage>2329</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">30338529</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>LZ</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Bo</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New arylpyrazoline-coumarins: synthesis and anti-inflammatory
activity</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>138</volume>:<fpage>170</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">28667873</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Somakala</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Amir</surname><given-names>M</given-names></name></person-group>
<article-title>Synthesis,
characterization and pharmacological evaluation of pyrazolyl urea derivatives as
potential anti-inflammatory agents</article-title>. <source>Acta Pharm Sin B</source>
<year>2017</year>;<volume>7</volume>:<fpage>230</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">28303231</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>XL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>(7<italic>R</italic>, 8<italic>S</italic>)-dehydrodiconiferyl alcohol
suppresses lipopolysaccharide-induced inflammatory responses in BV2 microglia by
inhibiting MAPK signaling</article-title>. <source>Neurochem Res</source>
<year>2016</year>;<volume>41</volume>:<fpage>1570</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26961887</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>ZY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of novel sesquistilbene indanone analogues as potent
antiinflammatory agents</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>113</volume>:<fpage>63</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">26922229</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gibson</surname><given-names>TB</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mitogen-activated protein (MAP) kinase pathways: regulation and
physiological functions</article-title>. <source>Endocr Rev</source>
<year>2001</year>;<volume>22</volume>:<fpage>153</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">11294822</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>DA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of
4-phenylthieno[2,3-e][1,2,4]triazolo[4,3-a]pyrimidine-5(4<italic>H</italic>)-one
derivatives and evaluation of their anti-inflammatory activity</article-title>.
<source>Lett Drug Des Discov</source>
<year>2015</year>;<volume>13</volume>:<fpage>141</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>XY</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>CX</given-names></name>, <name name-style="western"><surname>Chai</surname><given-names>KY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anti-inflammatory activity evaluation of novel
7-alkoxy-1-amino-4,5-dihydro[1,2,4]triazole[4,3-a]quinolines</article-title>.
<source>Arch Pharm Chem Life Sci</source>
<year>2008</year>;<volume>341</volume>:<fpage>288</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>XY</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>XQ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anti-inflammatory activity evaluation of some novel 6-alkoxy
(phenoxy)-[1,2,4]triazolo[3,4-a]phthalazine-3-amine derivatives</article-title>.
<source>Eur J Med Chem</source>
<year>2010</year>;<volume>45</volume>:<fpage>4807</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">20813431</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>CX</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anti-inflammatory activity evaluation of a novel series of
6-phenoxy-[1,2,4]triazolo[3,4-a]phthalazine-3-carboxamide derivatives</article-title>.
<source>Bioorg Med Chem Lett</source>
<year>2016</year>;<volume>26</volume>:<fpage>1576</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26876930</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#x000f6;s</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jenck</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>JR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of
substituted 2-(Indol-1-yl)-1-methylethylamines and 2-(Indeno[1,2-b]pyrrol-
1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive
disorder</article-title>. <source>J Med Chem</source>
<year>1997</year>;<volume>40</volume>:<fpage>2762</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9276022</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>CT</given-names></name></person-group>
<article-title>Ytterbium
triflate-catalyzed heterocyclization of 1,2-phenylenediamines and alkyl oxalates under
solvent-free conditions via Phillips reaction: a facile synthesis of
quinoxaline-2,3-diones derivatives</article-title>. <source>Synthetic Commun</source>
<year>2004</year>;<volume>34</volume>:<fpage>1349</fpage>&#x02013;<lpage>57</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Shreedhar</surname><given-names>D</given-names></name></person-group>
<article-title>Antimicrobial studies of Co (II), Ni (II), Cu (II) and Zn (II) complexes
derived from Schiff bases of 3-formyl quinoline and
3-hydrazinoquinoxalin-2(1<italic>H</italic>) one</article-title>. <source>Rasayan J
Chem</source>
<year>2012</year>;<volume>5</volume>:<fpage>234</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeom</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Min</surname><given-names>JH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Xanthii fructus inhibits inflammatory responses in LPS-stimulated RAW 264.7
macrophages through suppressing NF-&#x003ba;B and JNK/p38 MAPK</article-title>. <source>J
Ethnopharmacol</source>
<year>2015</year>;<volume>176</volume>:<fpage>394</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">26560439</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aktan</surname><given-names>F</given-names></name></person-group>
<article-title>iNOS-mediated nitric oxide production and its regulation</article-title>.
<source>Life Sci</source>
<year>2004</year>;<volume>75</volume>:<fpage>639</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">15172174</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>IZ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>18 a-Glycyrrhetinic acid monoglucuronide as an anti-inflammatory agent
through suppression of the NF-&#x003ba;B and MAPK signaling pathway</article-title>. <source>Med
Chem Commun</source>
<year>2017</year>;<volume>8</volume>:<fpage>1498</fpage>&#x02013;<lpage>504</lpage>.</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sogo</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Terahara</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hisanaga</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Anti-inflammatory activity and molecular mechanism of delphinidin
3-sambubioside, a Hibiscus anthocyanin</article-title>. <source>Biofactors</source>
<year>2015</year>;<volume>41</volume>:<fpage>58</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">25728636</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tageldin</surname><given-names>GN</given-names></name>, <name name-style="western"><surname>Fahmy</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Ashour</surname><given-names>HM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and evaluation of some pyrazolo[3,4-d]pyrimidines as
anti-inflammatory agents</article-title>. <source>Bioorg Chem</source>
<year>2018</year>;<volume>78</volume>:<fpage>358</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">29627656</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murahari</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mahajan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Neeladri</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ligand based design and synthesis of pyrazole based derivatives as
selective COX-2 inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>86</volume>:<fpage>583</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">30782576</pub-id></mixed-citation></ref></ref-list></back></article>
